A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis.

Background: Pruritus is the hallmark clinical sign of atopic dermatitis (AD) in dogs. Lokivetmab, a caninized anti-canine IL-31 monoclonal antibody, reduced pruritus and associated inflammatory skin lesions in a proof-of-concept study in dogs with AD.

Hypothesis/objectives: The objective was to describe lokivetmab dose response in a randomized, double blind, placebo-controlled trial.

Clinical efficacy and safety of dexmedetomidine used as a preanesthetic prior to general anesthesia in cats.

Objective: To evaluate the clinical efficacy of dexmedetomidine as a preanesthetic medication administered prior to anesthetic induction with ketamine or propofol and with or without isoflurane for maintenance of anesthesia.

Design: Randomized, blinded, controlled clinical trial.

Animals: 184 client-owned cats.

Efficacy of sublingual administration of detomidine gel for sedation of horses undergoing veterinary and husbandry procedures under field conditions.

Objective: To determine whether sublingual detomidine gel administration to horses would be effective in providing an appropriate degree of sedation and restraint to facilitate completion of veterinary and husbandry procedures under field conditions.

Design: Multicenter, prospective, randomized, blinded, placebo-controlled clinical study.

Animals: 270 client-owned horses known to require sedation or strong restraint to enable veterinary and husbandry procedures to be performed.